Short course of systemic corticosteroids in sinonasal polyposis: a double-blind, randomized, placebo-controlled trial with evaluation of outcome measures.

Abstract

BACKGROUND:

Topical and systemic corticosteroids are the first choice in medical treatments for sinonasal polyposis, but surprisingly, there is no high-level evidence for the efficacy of oral corticosteroids.

OBJECTIVE:

The aim of this study was to establish the efficacy of a short course of oral prednisolone in ameliorating the symptoms of sinonasal polyposis, as well as reducing mucosal inflammation assessed by means of nasendoscopy and magnetic resonance imaging (MRI). A secondary aim was to evaluate the relationship between outcome measures.

METHODS:

Subjects with symptomatic endoscopically diagnosed sinonasal polyposis received 50 mg of prednisolone daily for 14 days or placebo. Outcome was quantified by using the modified 31-item Rhinosinusitis Outcome Measure questionnaire, physician's assessment, nasendoscopy with photography, and MRI.

RESULTS:

There were 20 subjects in each treatment group. Only the prednisolone-treated group showed significant improvement in nasal symptoms (P < .001). The Rhinosinusitis Outcome Measure score improved in both groups, but the prednisolone-treated group had significantly greater improvement than the placebo group (P < .001). Objectively, there was significant reduction in polyp size, as noted with nasendoscopy (P < .001) and MRI (P < .001), only in the prednisolone-treated group. The outcome measures correlated with each other; the highest level of correlation was between the objective measures of nasendoscopy and MRI (R(2) = 0.76, P < .001). There were no significant adverse events.

CONCLUSION:

This trial clearly establishes clinically significant improvement in the symptoms and pathology of sinonasal polyposis with a short course of systemic corticosteroids. MRI scanning and quantitative nasendoscopic photography are objective and valid tools for assessing the outcome of treatment in this condition.

CLINICAL IMPLICATIONS:

A 14-day course of 50 mg of prednisolone is safe and effective therapy for symptomatic nasal polyposis.

• Authors: Pravin Hissaria, William Smith, Peter J Wormald, James Taylor, Mathew Vadas, David Gillis, Frank Kette
• Journal: The Journal of allergy and clinical immunology (J Allergy Clin Immunol) Vol. 118 Issue 1 Pg. 128-33 (Jul 2006) ISSN: 0091-6749 [Print] United States
• PMID: 16815148 (Publication Type: Journal Article, Randomized Controlled Trial)

Chemical References

• Prednisolone

Topics

• Adult
• Aged
• Double-Blind Method
• Female
• Humans
• Magnetic Resonance Imaging
• Male
• Middle Aged
• Nasal Polyps (drug therapy, pathology)
• Outcome Assessment, Health Care
• Prednisolone (adverse effects, therapeutic use)